MWN109
Clinical Trials

View on ClinicalTrials.gov

View on ClinicalTrials.gov
Two Formulations
MWN109 Injection | MWN109 Tablet | |
Route | Subcutaneous | Oral |
Dosing | Once weekly | Once daily |
Mechanism | GLP-1/GIP/GCG | GLP-1/GIP/GCG |
Indication | Overweight & obesity | Overweight & obesity |
Development | Phase III | Phase II |
Key differentiation | Advanced clinical development | Needle-free administration |
Development Highlights
1. Triple-Receptor Agonism
Designed to simultaneously activate GLP-1, GIP and GCG receptors, integrating complementary mechanisms involved in glycemic control, appetite regulation and energy expenditure in a single therapeutic approach.
2. Dual-Formulation Strategy
Available as both a once-weekly injectable and a once-daily oral formulation, providing complementary administration options and extending the potential of triple-agonist therapy from injectable to needle-free oral treatment.
3. Advanced Clinical Development
The injectable formulation has advanced to Phase III development in overweight and obesity, while the oral formulation provides a differentiated follow-on opportunity, supporting the development of a broader MWN109 metabolic franchise.
Thank You for Your Attention on Lepu Medical!
Email us with any questions or inquiries or use our contact data. We would be happy to answer your questions.
